Abstract
Purpose
Epidermal growth factor (EGF) family plays critical roles in intestinal epithelial growth and transformation. Amphiregulin (AREG) is a member of the EGF family, and has been suggested to be more important to tumor versus normal growth. The precise roles of AREG in colorectal carcinogenesis have not been thoroughly elucidated.
Methods
AREG expression was analyzed in colon cancer specimens using immunohistochemistry. Genetically disruption of AREG in APC min/+ mouse was achieved by crossbreeding AREG knockout mouse with APC min/+ mice. Knockdown AREG expression was accomplished by using plasmid-based RNA interference. Growth-stimulatory effects of AREG were determined using cell co-culture systems.
Results
AREG was expressed in both epithelial and stromal compartments in human colon cancer; however, it was regulated by different mechanisms. AREG was predominantly regulated at transcriptional level in colon cancer cells while both transcriptional and post-transcriptional mechanisms were involved in colon cancer derived myofibroblasts. Functionally, knockout of AREG strongly reduced tumorigenicity in APC min/+ mice. Immunohistochemistry demonstrated the coordinate expression of AREG, EGF receptor activity, and cell proliferation marker in APC min/+ mouse adenoma, indicating the growth-stimulatory function of AREG signaling in tumor development. Furthermore, we demonstrated that AREG may stimulate tumor cell growth through both autocrine and paracrine pathways in cell culture models. Knockdown of AREG impaired the ability of anchorage-independent growth of transformed intestinal epithelial cells. On the other hand, myofibroblast-produced AREG stimulated the growth of colon cancer cells when co-cultured in extracellular matrix.
Conclusions
AREG plays pro-neoplastic roles in colorectal carcinogenesis and may be targeted for colon cancer prevention and treatment.
Similar content being viewed by others
References
Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science. 1990;247:322–4.
Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66:589–600.
Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science. 1991;253:665–9.
Kinzler WK, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–70.
Karnes Jr WE, Weller SG, Adjei PN, Kottke TJ, Glenn KS, Gores GJ, et al. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology. 1998;114:930–9.
Roh H, Pippin J, Drebin JA. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res. 2000;60:560–5.
Oldham SM, Cox AD, Reynolds ER, Sizemore NS, Coffey RJJ, Der CJ. Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade. Oncogene. 1998;16:2565–73.
Sheng H, Shao H, DuBois RN. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem. 2001;276:14498–504.
Podolsky DK. Peptide growth factors in gastrointestinal mucosal growth. In: Johnson LR, editor. Physiology of the gastrointestinal tract. 3rd ed. New York: Raven; 1994. p. 129–67.
Jones MK, Tomikawa M, Mohajer B, Tarnawski AS. Gastrointestinal mucosal regeneration: role of growth factors. Front Biosci. 1999;4:D303–9.
Polk DB, Barnard JA. Hormones and growth factors in intestinal development. In: Sanderson IR, Walker A, editors. Development of the gastrointestinal tract. Hamilton, Ontario, Canada: Decker; 1999. p. 37–55.
Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol. 2007;18:963–4.
Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091–6.
Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, et al. Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A. 1991;88:7792–6.
Shao J, Lee SB, Guo H, Evers BM, Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res. 2003;63:5218–23.
Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Lee DC, Prieto J, et al. Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology. 2005;128:424–32.
Chang SH, Ai Y, Breyer RM, Lane TF, Hla T. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res. 2005;65(11):4496–9.
Shao J, Sheng H. Amphiregulin promotes intestinal epithelial regeneration: roles of intestinal subepithelial myofibroblasts. Endocrinology. 2010;151:3728–37.
Yamada M, Ichikawa Y, Yamagishi S, Momiyama N, Ota M, Fujii S, et al. Amphiregulin is a promising prognostic marker for liver metastases of colorectal cancer. Clin Cancer Res. 2008;14:2351–6.
Prescott SM, White RL. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. Cell. 1996;87:783–6.
Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–73.
Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology. 2005;128:1445–61.
Shao J, Sheng GG, Mifflin RC, Powell DW, Sheng H. Roles of myofibroblasts in prostaglandin E2-stimulated intestinal epithelial proliferation and angiogenesis. Cancer Res. 2006;66:846–55.
Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 1999;126:2739–50.
Sheng H, Shao J, Townsend Jr CM, Evers BM. Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells. Gut. 2003;52:1472–8.
Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, et al. A selective cyclooxygenase-2 inhibitor suppresses the growth of H-ras transformed rat intestinal epithelial cells. Gastroenterology. 1997;113:1883–91.
Shao J, Sheng H. Prostaglandin E2 induces the expression of IL-1 > {alpha} in colon cancer cells. J Immunol. 2007;178:4097–103.
Adegboyega PA, Mifflin RC, DiMari JF, Saada JI, Powell DW. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med. 2002;126:829–36.
De Luca A, Arra C, D’Antonio A, Casamassimi A, Losito S, Ferraro P, et al. Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. Oncogene. 2000;19:5863–71.
Oshima M, Murai N, Kargman S, Arguello M, Luk P, Kwong E, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001;61:1733–40.
Reuter BK, Zhang XJ, Miller MJ. Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer. 2002;2:19.
Shao J, Evers BM, Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem. 2004;279:14287–93.
Johansson CC, Yndestad A, Enserink JM, Ree AH, Aukrust P, Tasken K. The epidermal growth factor-like growth factor amphiregulin is strongly induced by the adenosine 3′,5′-monophosphate pathway in various cell types. Endocrinology. 2004;145:5177–84.
Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, et al. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999;98:663–73.
Guhaniyogi J, Brewer G. Regulation of mRNA stability in mammalian cells. Gene. 2001;265:11–23.
Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci USA. 1986;83:1670–4.
Sirenko OI, Lofquist AK, DeMaria CT, Morris JS, Brewer G, Haskill JS. Adhesion-dependent regulation of an A+U rich element binding activity associated with AUF1. Mol Cell Biol. 1997;17:3898–906.
Sachs AB. Messenger RNA degradation in eukaryotes. Cell. 1993;74:413–21.
Sizemore N, Cox AD, Barnard JA, Oldham SM, Reynolds ER, Der CJ, et al. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. Gastroenterology. 1999;117:567–76.
Acknowledgments
This study was supported by Grant number: DK086558 from National Institute of Health, USA.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guzman, M.J., Shao, J. & Sheng, H. Pro-Neoplastic Effects of Amphiregulin in Colorectal Carcinogenesis. J Gastrointest Canc 44, 211–221 (2013). https://doi.org/10.1007/s12029-012-9474-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-012-9474-2